|
Coronary Arteriosclerosis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The BRAP rs11066001 gene is associated with the extent of coronary atherosclerosis and has a synergistic effect with diabetes on the occurrence of significant CAD in the Chinese population.
|
22085839 |
2011 |
|
Coronary Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Validation of eight genetic risk factors in East Asian populations replicated the association of BRAP with coronary artery disease.
|
19713974 |
2009 |
|
Coronary Artery Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the replication phase, involving 3052 cases and 6335 controls, 12 SNPs were tested; CAD association was replicated and/or verified for 4 (of 12) SNPs from 3 loci: near BRAP and ALDH2 on 12q24 (P=1.6 × 10(-34)), HLA-DQB1 on 6p21 (P=4.7 × 10(-7)), and CDKN2A/B on 9p21 (P=6.1 × 10(-16)).
|
21971053 |
2012 |
|
Coronary Artery Disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
In addition, a combined analysis of BRAP and another CAD locus on 9p21 suggested that these loci had a synergistic role in the susceptibility.
|
19713974 |
2009 |
|
Coronary Artery Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
The single nucleotide polymorphisms (SNPs) in the gene of breast cancer suppressor protein (BRCA1)-associated protein (BRAP) are significantly associated with coronary artery disease, but the molecular mechanisms are not understood.
|
22965072 |
2013 |
|
Coronary Artery Disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The BRAP rs11066001 gene is associated with the extent of coronary atherosclerosis and has a synergistic effect with diabetes on the occurrence of significant CAD in the Chinese population.
|
22085839 |
2011 |
|
Glioma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.
|
20484439 |
2010 |
|
Glioma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We found that in glioma patients BRAP expression was associated with a favourable prognosis.
|
31776938 |
2020 |
|
Glioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Autophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition-induced apoptotic death.
|
27818246 |
2017 |
|
Metabolic Syndrome X
|
0.030 |
Biomarker
|
disease |
BEFREE |
A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains.
|
22022282 |
2011 |
|
Metabolic Syndrome X
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Our data provide evidence that the SNPs (rs11066001 and rs3782886) in BRAP decrease the risk of MetS, and associations of the SNPs with various components of MetS are different.
|
22965072 |
2013 |
|
Metabolic Syndrome X
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Increased risk of developing metabolic syndrome (MetS) has been associated with the APOA5, APOC1, BRAP, BUD13, CETP, LIPA, LPL, PLCG1, and ZPR1 genes.
|
27827461 |
2016 |
|
Lewy Body Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
The FDG-PET and IMP-SPECT derived CIS ratios are both useful for differentiating between AD and DLB.
|
31199036 |
2019 |
|
Lewy Body Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Diagnosis of dementia with Lewy bodies: can <sup>123</sup>I-IMP and <sup>123</sup>I-MIBG scintigraphy yield new core features?
|
27897064 |
2017 |
|
Lewy Body Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the dementia groups, receiver operating characteristic analysis of the CIS ratio showed significant accuracy for differentiating between AD and DLB on both FDG PET and IMP SPECT.
|
30075285 |
2018 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Information is lacking, however, regarding the diagnostic value of the CIS on FDG PET or <sup>123</sup>I-iodoamphetamine single-photon emission computed tomography (IMP SPECT) for differentiating between mild cognitive impairment (MCI) due to Alzheimer's disease (AD) (MCI-AD) and MCI due to DLB (MCI-DLB).
|
30075285 |
2018 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
The FDG-PET and IMP-SPECT derived CIS ratios are both useful for differentiating between AD and DLB.
|
31199036 |
2019 |
|
Blast Phase
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
|
9042310 |
1997 |
|
Blast Phase
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The decrease in IMP DH activity, GTP concentration, and expression of c-Ki-ras oncogene were early markers of the successful chemotherapeutic impact of tiazofurin in a patient with chronic granulocytic leukemia in blast crisis.
|
1705812 |
1991 |
|
Mild cognitive disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
Information is lacking, however, regarding the diagnostic value of the CIS on FDG PET or <sup>123</sup>I-iodoamphetamine single-photon emission computed tomography (IMP SPECT) for differentiating between mild cognitive impairment (MCI) due to Alzheimer's disease (AD) (MCI-AD) and MCI due to DLB (MCI-DLB).
|
30075285 |
2018 |
|
Mild cognitive disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
The FDG-PET derived CIS ratio is more valuable than the IMP-SPECT derived CIS ratio for differential diagnosis in patients with MCI.
|
31199036 |
2019 |
|
Anemia, Sickle Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regional cerebral blood flow (CBF) were obtained from ASL and <sup>123</sup>I-IMP single-photon emission computed tomography (SPECT) images by volume-of-interest analysis in patients with SCD (n = 16).
|
30216759 |
2018 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
BRCA-1 associated protein (BRAP), a newly identified risk gene for MI, aggravates the inflammatory response in atherosclerosis.
|
23356535 |
2013 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
BRCA-1 associated protein (BRAP), a newly identified risk gene for MI, aggravates the inflammatory response in atherosclerosis.
|
23356535 |
2013 |
|
Bacteremia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although in-hospital mortality rates were similar between cases and controls (14.3% versus 13.3%), the in-hospital mortality of patients with IMP-producing E. cloacae-caused bacteremia was significantly higher (40%) than the rate in controls.
|
24709261 |
2014 |